Biden Administration Outlines Plan to Effectively Remove Patent Rights from Certain Prescription Medications

Thomas Sullivan

Summary

Explore the Biden Administration’s draft proposal on “march-in” rights for patented drugs, aiming to license drugs developed with taxpayer funds if not reasonably priced for Americans. The proposal, currently under agency evaluation, raises concerns about defining “reasonable” pricing and potential impacts on drug availability and safety.

Did you find this helpful?

Thank you for your feedback!

Sign Up for Research & Product Updates